The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination
AML patients with FAT1 mutations have better initial induction chemotherapy efficacy with venetoclax-based regimens compared to wild-type patients, and there is a trend toward improved PFS. This may be related to the improved efficacy and prognosis in P53 mutation-positive patients.
Authors
- Junting Li
- Yongqian Jia
- Junxia Huang (ORCID: https://orcid.org/0000-0003-4084-9159)
- Tao Wang (ORCID: https://orcid.org/0000-0003-4948-9073)
- Guang Lu
- Weiwei Mou
Institutions
- Qingdao University (CN)
- Shanghai Jiao Tong University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Shengli Oilfield Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.3389/fonc.2025.1456832
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77